Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study.
暂无分享,去创建一个
W. Furman | C. Pratt | B. Leventhal | K. McClain | D. Strother | B. Bell | Wayne L. Furman | Kenneth L. McClain | Douglas Strother | Kenneth L. McClain | Bennett L. Leventhal | Charles B. Pratt
[1] J. Ihle,et al. Recombinant human TNF-alpha stimulates the secretion of granulocyte colony-stimulating factor in vivo. , 1992, Leukemia.
[2] G. Budd,et al. A Southwest oncology group phase ii trial of recombinant tumor necrosis factor in metastatic breast cancer , 1991, Cancer.
[3] B. Storer,et al. Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. , 1991, Cancer research.
[4] J. Markovits,et al. Potentiation of tnf‐mediated cell killing by VP‐16: Relationship to DNA single‐strand break formation , 1990, International journal of cancer.
[5] F. Coffman,et al. Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II. , 1990, Journal of immunology.
[6] N. Kemeny,et al. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma , 1990, Cancer.
[7] M. Mattern,et al. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. , 1990, Cancer research.
[8] A. Rudolph,et al. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. , 1989, Journal of biological response modifiers.
[9] J. Krischer,et al. Mortality in pediatric phase I clinical trials. , 1989, Journal of the National Cancer Institute.
[10] R. Figlin,et al. Pulmonary toxicity of recombinant human tumor necrosis factor. , 1989, Chest.
[11] D. Spriggs,et al. Tumor necrosis factor: still a promising agent. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Gabrilove,et al. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Kovach,et al. A phase I clinical trial of recombinant human tumor necrosis factor , 1988, Cancer.
[14] A. Malik,et al. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Kufe,et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. , 1988, Journal of the National Cancer Institute.
[16] R. Kurzrock,et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Shau. Characteristics and mechanism of neutrophil-mediated cytostasis induced by tumor necrosis factor. , 1988, Journal of immunology.
[18] D. Kufe,et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Gabrilove,et al. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Newell,et al. In pursuit of evidence based integrated care , 1987, British Journal of Cancer.
[21] M. Rosenblum,et al. Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.
[22] A. Matter,et al. Anti‐tumor effects of tumor necrosis factor in combination with chemotherapeutic agents , 1987, International Journal of Cancer.
[23] H. Koeffler,et al. Recombinant human TNF induces production of granulocyte–monocyte colony-stimulating factor , 1986, Nature.
[24] W. Fiers,et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. , 1986, Cancer research.
[25] W. Fiers,et al. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. , 1986, European journal of cancer & clinical oncology.
[26] B. Aggarwal,et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.
[27] N. Satomi,et al. Cytotoxic activity of tumor necrosis factor (TNF) on human cancer cells in vitro. , 1981, The Japanese journal of experimental medicine.
[28] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Schilling,et al. Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction , 1992, Cancer.
[30] W. Coley. The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .